Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (GB:0XOD)
LSE:0XOD
0XOD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $18.50
Previous CloseN/A
Volume100.00
Average Volume (3M)34.23K
Market Cap
$685.62M
Enterprise Value$246.01M
Total Cash (Recent Filing)$195.89M
Total Debt (Recent Filing)$124.95M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 19, 2025EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding46,107,452
10 Day Avg. Volume56,311
30 Day Avg. Volume34,231
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-2.30
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit2.99
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
$33.43Price Target Upside125.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Urogen Pharma News
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst is upgrading the rating to Buy from Neutral, and instituting a 12-month price target of $50.
EfficacyZUSDURI delivers 78% complete response for patients at 3 months, and of those patients 79% remained event-free 12 months later.
FDA ApprovalUroGen Pharma announced that the FDA had approved ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer.
Bears Say
FDA RequirementsThe FDA may require additional clinical efficacy data from a randomized, controlled study, which could take two to three years to complete, increasing uncertainty for UGN-102's approval.
Regulatory ChallengesDeficiencies in the pivotal ENVISION trial, such as its non-randomized, single-arm design, and early termination of the ATLAS trial have been highlighted, challenging the approval of UGN-102.
Revenue ForecastRevised projections indicate a significant decline in revenue forecasts for 2025 and 2026 due to the expected non-approval of UGN-102.
Options Prices
Currently, No data available
---
Ownership Overview
2.22% Insiders
2.40%
Mutual Funds
52.18% Other Institutional Investors
37.95% Public Companies and Individual Investors
0XOD FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest share price was $3.61 and its highest was $18.50 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $685.62M.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Aug 19, 2025 which is in 59 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on May 12, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.121.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.82.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,107,452 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 6.03%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in GB:0XOD
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.43 (125.12% Upside)
$33.43 (125.12% Upside)
Blogger Sentiment
Bullish
GB:0XOD Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.45%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
0XOD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in UGN-102's FDA review process, strong clinical trial results, and a substantial market opportunity. JELMYTO's revenue growth and a strong financial position also contribute positively. However, there are concerns about the single-arm nature of the ENVISION trial, increased expenses, and net loss. The highlights and lowlights are relatively balanced.Read More>0XOD Stock 12 Month Forecast
Average Price Target
$33.43
▲(125.12%Upside)
Technical Analysis
Niagen Bioscience
―
Savara
―
Arvinas Holding Company
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―